← Back to Search

Local Anesthetic

Local Anesthesia for Abdominal Surgery Pain Management (CLEVELAND Trial)

Phase 3
Recruiting
Led By Alparslan Turan, MD
Research Sponsored by The Cleveland Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Expected requirement for parenteral opioids for at least 72 hours for postoperative pain
Scheduled for elective open or laparoscopic-assisted abdominal surgery
Must not have
Surgeries with high port sites
Weight <50 kg
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 72 hours
Awards & highlights

Summary

This trial will compare the efficacy of three different types of local anesthesia for major abdominal surgery in terms of pain relief and duration of effect.

Who is the study for?
This trial is for adults aged 18-85 scheduled for major abdominal surgery, who will stay in the hospital at least three nights and need opioids post-surgery. They must be able to use IV pain control systems and not have liver or kidney disease, be pregnant/breastfeeding, on certain blood thinners, have high surgical port sites, weigh under 50 kg, or be allergic to bupivacaine.
What is being tested?
The study tests the effectiveness of TAP blocks using liposomal bupivacaine (a long-lasting numbing medication), plain bupivacaine (standard numbing medication), or saline (placebo) in managing pain after abdominal surgery. It measures how long the pain relief lasts, opioid use, and patient-reported pain levels over up to 72 hours.
What are the potential side effects?
Potential side effects may include reactions at the injection site like swelling or infection; numbness beyond desired areas; toxicity from local anesthetics leading to symptoms such as ringing ears, metallic taste in mouth, numbness around mouth or tongue tip.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I will need strong painkillers through an IV for at least 3 days after surgery.
Select...
I am scheduled for elective surgery in my abdomen.
Select...
My health is good to moderately impaired.
Select...
I am between 18 and 85 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had surgery involving high port sites.
Select...
I weigh less than 50 kg.
Select...
I cannot have TAP blocks due to my blood thinner medication.
Select...
I am not pregnant or breastfeeding.
Select...
My kidney function is impaired, with creatinine levels twice the normal.
Select...
My liver enzymes are twice the normal level.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~72 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 72 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Time to return of sensation
Secondary study objectives
Opioid Consumption

Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: liposomal bupivacaineActive Control1 Intervention
40 ml of plain bupivacaine 0.25% will be mixed with 20 ml liposomal bupivacaine and 20 ml of saline. 20 ml of the mix will be injected at each location of the 4-quadrant TAP block.
Group II: plain bupivacaineActive Control1 Intervention
50 ml of plain bupivacaine 0.5% will be combined with 30 ml of normal saline making a total of 80 ml. 20 ml will be injected at each location of the 4-quadrant TAP block.
Group III: Normal SalinePlacebo Group1 Intervention
patients will receive total of 80 ml of normal saline, injected 20 ml in each of the four-quadrant sites.

Find a Location

Who is running the clinical trial?

The Cleveland ClinicLead Sponsor
1,045 Previous Clinical Trials
1,370,438 Total Patients Enrolled
Alparslan Turan, MDPrincipal InvestigatorThe Cleveland Clinic
7 Previous Clinical Trials
5,472 Total Patients Enrolled

Media Library

Liposomal bupivacaine (Local Anesthetic) Clinical Trial Eligibility Overview. Trial Name: NCT04685876 — Phase 3
Abdominal Surgery Research Study Groups: liposomal bupivacaine, plain bupivacaine, Normal Saline
Abdominal Surgery Clinical Trial 2023: Liposomal bupivacaine Highlights & Side Effects. Trial Name: NCT04685876 — Phase 3
Liposomal bupivacaine (Local Anesthetic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04685876 — Phase 3
~12 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top